APA (7th ed.) Citation

K, G., CL, H., NJ, R., M, J., T, H., J, K., . . . SC, C. (2022). Introducing 1,3-beta-d-glucan for screening and diagnosis of invasive fungal diseases in Australian high-risk haematology patients: Is there a clinical benefit? Internal medicine journal, 52(3), 426. https://doi.org/10.1111/imj.15046

Chicago Style (17th ed.) Citation

K, Garnham, et al. "Introducing 1,3-beta-d-glucan for Screening and Diagnosis of Invasive Fungal Diseases in Australian High-risk Haematology Patients: Is There a Clinical Benefit?" Internal Medicine Journal 52, no. 3 (2022): 426. https://doi.org/10.1111/imj.15046.

MLA (9th ed.) Citation

K, Garnham, et al. "Introducing 1,3-beta-d-glucan for Screening and Diagnosis of Invasive Fungal Diseases in Australian High-risk Haematology Patients: Is There a Clinical Benefit?" Internal Medicine Journal, vol. 52, no. 3, 2022, p. 426, https://doi.org/10.1111/imj.15046.